Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887053600> ?p ?o ?g. }
- W2887053600 endingPage "167.e1" @default.
- W2887053600 startingPage "158" @default.
- W2887053600 abstract "BackgroundThe impact of dupilumab, an anti–interleukin (IL) 4 receptor α antibody that inhibits IL-4 and IL-13 signaling, on vaccine responses of patients with atopic dermatitis (AD) is unknown.ObjectivesTo assess T-cell–dependent and T-cell–independent humoral immune responses to tetanus and meningococcal vaccines, IgE seroconversion to tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination, and dupilumab efficacy and safety.MethodsIn a randomized, double-blinded, placebo-controlled study (NCT02210780), adults with moderate-to-severe AD received dupilumab (300 mg) or placebo weekly for 16 weeks, and single doses of Tdap and quadrivalent meningococcal polysaccharide vaccines at week 12. Primary endpoint was proportion of patients achieving satisfactory IgG response to tetanus toxoid at week 16.ResultsIn total, 178 patients completed the study. Similar positive immune responses (≥4-fold increase in antibody titer, or an antibody titer of ≥8) were achieved in the dupilumab and placebo groups to tetanus (83.3% and 83.7%, respectively) and meningococcal polysaccharide (86.7% and 87.0%, respectively). Dupilumab significantly decreased total serum IgE; most dupilumab-treated patients were Tdap-IgE seronegative at week 32 (62.2% dupilumab and 34.8% placebo). Dupilumab improved key AD efficacy endpoints (P < .001). Injection-site reactions and conjunctivitis were more common with dupilumab; AD exacerbations more frequent with placebo.LimitationPatients’ prior vaccination status was not available before enrollment.ConclusionDupilumab did not affect responses to the vaccines studied, significantly decreased IgE, and improved measures of AD severity versus placebo, with an acceptable safety profile. The impact of dupilumab, an anti–interleukin (IL) 4 receptor α antibody that inhibits IL-4 and IL-13 signaling, on vaccine responses of patients with atopic dermatitis (AD) is unknown. To assess T-cell–dependent and T-cell–independent humoral immune responses to tetanus and meningococcal vaccines, IgE seroconversion to tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination, and dupilumab efficacy and safety. In a randomized, double-blinded, placebo-controlled study (NCT02210780), adults with moderate-to-severe AD received dupilumab (300 mg) or placebo weekly for 16 weeks, and single doses of Tdap and quadrivalent meningococcal polysaccharide vaccines at week 12. Primary endpoint was proportion of patients achieving satisfactory IgG response to tetanus toxoid at week 16. In total, 178 patients completed the study. Similar positive immune responses (≥4-fold increase in antibody titer, or an antibody titer of ≥8) were achieved in the dupilumab and placebo groups to tetanus (83.3% and 83.7%, respectively) and meningococcal polysaccharide (86.7% and 87.0%, respectively). Dupilumab significantly decreased total serum IgE; most dupilumab-treated patients were Tdap-IgE seronegative at week 32 (62.2% dupilumab and 34.8% placebo). Dupilumab improved key AD efficacy endpoints (P < .001). Injection-site reactions and conjunctivitis were more common with dupilumab; AD exacerbations more frequent with placebo. Patients’ prior vaccination status was not available before enrollment. Dupilumab did not affect responses to the vaccines studied, significantly decreased IgE, and improved measures of AD severity versus placebo, with an acceptable safety profile." @default.
- W2887053600 created "2018-08-22" @default.
- W2887053600 creator A5000478173 @default.
- W2887053600 creator A5005306967 @default.
- W2887053600 creator A5015905197 @default.
- W2887053600 creator A5029519205 @default.
- W2887053600 creator A5036235720 @default.
- W2887053600 creator A5045313467 @default.
- W2887053600 creator A5054320048 @default.
- W2887053600 creator A5060607282 @default.
- W2887053600 creator A5071078845 @default.
- W2887053600 creator A5077097587 @default.
- W2887053600 creator A5077395512 @default.
- W2887053600 creator A5080237247 @default.
- W2887053600 date "2019-01-01" @default.
- W2887053600 modified "2023-10-10" @default.
- W2887053600 title "Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis" @default.
- W2887053600 cites W1971402668 @default.
- W2887053600 cites W1977179623 @default.
- W2887053600 cites W1999426720 @default.
- W2887053600 cites W2012868073 @default.
- W2887053600 cites W2020452602 @default.
- W2887053600 cites W2039671472 @default.
- W2887053600 cites W2044404464 @default.
- W2887053600 cites W2063606276 @default.
- W2887053600 cites W2068176013 @default.
- W2887053600 cites W2068259827 @default.
- W2887053600 cites W2071140449 @default.
- W2887053600 cites W2081368043 @default.
- W2887053600 cites W2088529808 @default.
- W2887053600 cites W2092607772 @default.
- W2887053600 cites W2101401558 @default.
- W2887053600 cites W2105521580 @default.
- W2887053600 cites W2108545436 @default.
- W2887053600 cites W2115541330 @default.
- W2887053600 cites W2118630839 @default.
- W2887053600 cites W2120110016 @default.
- W2887053600 cites W2128589740 @default.
- W2887053600 cites W2146302565 @default.
- W2887053600 cites W2149132843 @default.
- W2887053600 cites W2160358721 @default.
- W2887053600 cites W2167829087 @default.
- W2887053600 cites W2174132185 @default.
- W2887053600 cites W2200308911 @default.
- W2887053600 cites W2266684950 @default.
- W2887053600 cites W2342693354 @default.
- W2887053600 cites W2419580390 @default.
- W2887053600 cites W2520200809 @default.
- W2887053600 cites W2524051065 @default.
- W2887053600 cites W2610814011 @default.
- W2887053600 cites W2771011851 @default.
- W2887053600 cites W2795335902 @default.
- W2887053600 cites W2803941918 @default.
- W2887053600 cites W2805002966 @default.
- W2887053600 doi "https://doi.org/10.1016/j.jaad.2018.07.048" @default.
- W2887053600 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30092324" @default.
- W2887053600 hasPublicationYear "2019" @default.
- W2887053600 type Work @default.
- W2887053600 sameAs 2887053600 @default.
- W2887053600 citedByCount "90" @default.
- W2887053600 countsByYear W28870536002019 @default.
- W2887053600 countsByYear W28870536002020 @default.
- W2887053600 countsByYear W28870536002021 @default.
- W2887053600 countsByYear W28870536002022 @default.
- W2887053600 countsByYear W28870536002023 @default.
- W2887053600 crossrefType "journal-article" @default.
- W2887053600 hasAuthorship W2887053600A5000478173 @default.
- W2887053600 hasAuthorship W2887053600A5005306967 @default.
- W2887053600 hasAuthorship W2887053600A5015905197 @default.
- W2887053600 hasAuthorship W2887053600A5029519205 @default.
- W2887053600 hasAuthorship W2887053600A5036235720 @default.
- W2887053600 hasAuthorship W2887053600A5045313467 @default.
- W2887053600 hasAuthorship W2887053600A5054320048 @default.
- W2887053600 hasAuthorship W2887053600A5060607282 @default.
- W2887053600 hasAuthorship W2887053600A5071078845 @default.
- W2887053600 hasAuthorship W2887053600A5077097587 @default.
- W2887053600 hasAuthorship W2887053600A5077395512 @default.
- W2887053600 hasAuthorship W2887053600A5080237247 @default.
- W2887053600 hasBestOaLocation W28870536001 @default.
- W2887053600 hasConcept C126322002 @default.
- W2887053600 hasConcept C141105273 @default.
- W2887053600 hasConcept C142724271 @default.
- W2887053600 hasConcept C159654299 @default.
- W2887053600 hasConcept C203014093 @default.
- W2887053600 hasConcept C204787440 @default.
- W2887053600 hasConcept C22070199 @default.
- W2887053600 hasConcept C27081682 @default.
- W2887053600 hasConcept C2777351567 @default.
- W2887053600 hasConcept C2778329239 @default.
- W2887053600 hasConcept C2779824493 @default.
- W2887053600 hasConcept C2779841045 @default.
- W2887053600 hasConcept C71924100 @default.
- W2887053600 hasConceptScore W2887053600C126322002 @default.
- W2887053600 hasConceptScore W2887053600C141105273 @default.
- W2887053600 hasConceptScore W2887053600C142724271 @default.
- W2887053600 hasConceptScore W2887053600C159654299 @default.
- W2887053600 hasConceptScore W2887053600C203014093 @default.
- W2887053600 hasConceptScore W2887053600C204787440 @default.